Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Br J Haematol. 2017 Jul 27;182(4):602–605. doi: 10.1111/bjh.14846

Figure 1A. Rates of vaso-occlusive crises 1 year prior and during the 1 year of erythropoiesis-stimulating agent (ESA) therapy.

Figure 1A

We did not observe increases in the rates of vaso-occlusive crises, given as median (range), with ESA only [2/year (0 – 7/year) vs. 2/year (0 – 6/year)], newly prescribed HC-only [2/year (0 – 11/year) vs. 2/year 0 – 10/year)], newly prescribed HC+ESA [1/year (0 – 9/year) vs. 1/year (0 – 7/year)] or stable HC+ESA [1/year (0 – 11/year) vs. 0/year (0 – 8/year)] from the year pre-ESA when compared to the year of ESA therapy, respectively.